-
Je něco špatně v tomto záznamu ?
Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro
H. Kostrhunova, O. Vrana, T. Suchankova, D. Gibson, J. Kasparkova, V. Brabec
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
20939593
DOI
10.1021/tx1002904
Knihovny.cz E-zdroje
- MeSH
- adukty DNA chemie MeSH
- cirkulární dichroismus MeSH
- cisplatina chemie toxicita MeSH
- denaturace nukleových kyselin MeSH
- DNA chemie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- oprava DNA MeSH
- organoplatinové sloučeniny chemie toxicita MeSH
- protinádorové látky chemie toxicita MeSH
- sekvence nukleotidů MeSH
- tranzitní teplota MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
cis-Amminedichlorido(cyclohexylamine)platinum(II) (JM118) is an antitumor Pt(II) analogue of cisplatin exhibiting considerably higher activity than cisplatin in human tumor cells. JM118 is also the major metabolite of the first orally administered Pt(IV) drug satraplatin. In an effort to design improved platinum antitumor agents, it is important to elucidate the biochemical factors that affect the cytotoxic properties of existing platinum drugs. Since DNA is considered the major pharmacological target of platinum drugs, the objective in the present work was to understand more fully the DNA binding mode of antitumor JM118. We examined the rate of aquation of the first chloride of bifunctional JM118 and found that it was considerably lower than that of cisplatin; consequently, the rate of the reaction of JM118 with DNA was lower compared to cisplatin. The influence of global modification by JM118 and its major site-specific adducts on DNA conformation by biochemical methods was investigated as well. While examination of the global modification revealed in several cases no substantial differences in the lesions induced by JM118 and cisplatin, DNA bending due to the 1,2-GG intrastrand adduct of JM118 was lower than that of cisplatin. The bending angles afforded by the adducts of JM118 were only slightly affected by the orientation of the cyclohexylamine ligand toward the 3' or 5' direction of the duplex. We also used in vitro assays that make it possible to monitor DNA repair synthesis by cell-free extracts and DNA-protein cross-linking to probe properties of DNA adducts of JM118. These results showed a higher DNA-protein cross-linking efficiency of JM118 and a less efficient removal from DNA of the adducts of JM118 in comparison with cisplatin. Thus, the results of the present work provide additional evidence that DNA binding of JM118 is in several aspects different from that of conventional cisplatin.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026736
- 003
- CZ-PrNML
- 005
- 20160322105533.0
- 007
- ta
- 008
- 120816s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1021/tx1002904 $2 doi
- 035 __
- $a (PubMed)20939593
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kostrhunová, Hana. $7 _AN047101 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 245 10
- $a Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro / $c H. Kostrhunova, O. Vrana, T. Suchankova, D. Gibson, J. Kasparkova, V. Brabec
- 520 9_
- $a cis-Amminedichlorido(cyclohexylamine)platinum(II) (JM118) is an antitumor Pt(II) analogue of cisplatin exhibiting considerably higher activity than cisplatin in human tumor cells. JM118 is also the major metabolite of the first orally administered Pt(IV) drug satraplatin. In an effort to design improved platinum antitumor agents, it is important to elucidate the biochemical factors that affect the cytotoxic properties of existing platinum drugs. Since DNA is considered the major pharmacological target of platinum drugs, the objective in the present work was to understand more fully the DNA binding mode of antitumor JM118. We examined the rate of aquation of the first chloride of bifunctional JM118 and found that it was considerably lower than that of cisplatin; consequently, the rate of the reaction of JM118 with DNA was lower compared to cisplatin. The influence of global modification by JM118 and its major site-specific adducts on DNA conformation by biochemical methods was investigated as well. While examination of the global modification revealed in several cases no substantial differences in the lesions induced by JM118 and cisplatin, DNA bending due to the 1,2-GG intrastrand adduct of JM118 was lower than that of cisplatin. The bending angles afforded by the adducts of JM118 were only slightly affected by the orientation of the cyclohexylamine ligand toward the 3' or 5' direction of the duplex. We also used in vitro assays that make it possible to monitor DNA repair synthesis by cell-free extracts and DNA-protein cross-linking to probe properties of DNA adducts of JM118. These results showed a higher DNA-protein cross-linking efficiency of JM118 and a less efficient removal from DNA of the adducts of JM118 in comparison with cisplatin. Thus, the results of the present work provide additional evidence that DNA binding of JM118 is in several aspects different from that of conventional cisplatin.
- 650 _2
- $a protinádorové látky $x chemie $x toxicita $7 D000970
- 650 _2
- $a sekvence nukleotidů $7 D001483
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cirkulární dichroismus $7 D002942
- 650 _2
- $a cisplatina $x chemie $x toxicita $7 D002945
- 650 _2
- $a DNA $x chemie $7 D004247
- 650 _2
- $a adukty DNA $x chemie $7 D018736
- 650 _2
- $a oprava DNA $7 D004260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a denaturace nukleových kyselin $7 D009691
- 650 _2
- $a organoplatinové sloučeniny $x chemie $x toxicita $7 D009944
- 650 _2
- $a tranzitní teplota $7 D044366
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vrána, Oldřich, $d 1956- $7 xx0097595 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Suchánková, Tereza, $d 1983- $7 mub2011617906 $u Department of Experimental Physics, Faculty of Sciences, Palacky University, 17. listopadu 12, 77146 Olomouc, Czech Republic
- 700 1_
- $a Gibson, Dan $u Department of Medicinal Chemistry and Natural Products, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
- 700 1_
- $a Kašpárková, Jana, $d 1969- $7 xx0068609 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Brabec, Viktor, $d 1944- $7 jo20010087133 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 773 0_
- $w MED00002106 $t Chemical research in toxicology $x 1520-5010 $g Roč. 23, č. 11 (2010), s. 1833-1842
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20939593 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160322105602 $b ABA008
- 999 __
- $a ok $b bmc $g 948778 $s 784082
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 23 $c 11 $d 1833-1842 $e 20101012 $i 1520-5010 $m Chemical research in toxicology $n Chem Res Toxicol $x MED00002106
- LZP __
- $b NLK122 $a Pubmed-20120816/11/01